시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 디피실 관련 설사 치료 시장 보고서(2025년)
Difficile-Associated Diarrhea Treatment Global Market Report 2025
상품코드 : 1686050
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,265,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,056,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,846,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

디피실 관련 설사 치료 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 항균제 치료 수요 증가, 기후 변화, 자기 투여 치료 수요 등에 기인한다고 생각됩니다.

소화기계 질환의 유병률 증가는 클로스트리듐 디피실 관련 설사증 시장의 성장의 원동력이 될 것으로 예측됩니다. 소화기 시스템의 정상적인 기능을 방해하는 질병군을 포함합니다. 곰팡이인 클로스트리듐 디피실은 염증을 유발하여 장의 내벽을 손상시키는 독소를 생산함으로써 장을 감염시킵니다. 무디피실 관련 설사와 관련된 증상을 관리하는 효과적인 치료에 대한 수요가 높아지고 있습니다. Crohn's and Colitis Canada의 데이터에 따르면, 2023년에는 추정 322,600명의 캐나다인이 염증성 장질환(IBD)과 함께 생활하고 있으며, 이는 인구의 약 0.82%를 차지합니다. 2035년까지 약 47만 명의 캐나다인이 IBD를 앓을 것으로 예상되며, 이는 인구의 약 1.1%, 즉 국민의 약 91명 중 1명에 해당합니다.

클로스트리듐 디피실 감염(CDI)의 유병률 증가는 클로스트리듐 디피실 관련 설사 치료 시장 확대의 주요 촉진요인이 될 것으로 예상됩니다. 로스트리듐 디피실 감염(CDI)은 클로스트리듐 디피실이라는 박테리아에 기인하며, 주로 대장을 침범하고, 대장의 내벽을 손상시키는 독소를 생산하며, 설사, 배 통증, 생명을 위협할 수 있는 합병증 등의 증상을 일으킵니다. 이를 수행하는 것은 DAD를 해결하고 해결하는 데 필수적입니다. Library of Medicine)의 데이터에서 연간 약 50 만명의 미국인이 C. difficile 감염을 앓고 있음을 나타내는 질병 대책 센터(Centers for Disease Control: CDC)의 추정치가 보고되었습니다. 이러한 사례 중 약 29,000명의 환자가 진단 후 한 달 이내에 사망하며, 이 중 15,000명의 사망이 C. difficile 감염과 직접적인 관련이 있는 것으로 추정됩니다.또한 약 83,000명의 환자가 적어도 1회는 재발하고, 29,000명이 30일 이내에 초기 진단을 받았습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Clostridium difficile-associated diarrhea, often resulting from antibiotic usage, is caused by a bacterium affecting the large intestine and necessitates treatment to manage the overgrowth of C. difficile and curb toxin production. Typical symptoms encompass watery diarrhea, diminished appetite, nausea, abdominal discomfort, and more.

The primary categories of treatments for C. difficile-associated diarrhea include narrow-spectrum antibiotics and broad-spectrum antibiotics. Narrow-spectrum antibiotics are a class of antimicrobial agents designed to target specific bacterial groups or subgroups. These treatments are accessible through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and serve diverse end users, such as hospitals, homecare, specialty clinics, and more.

The difficile-associated diarrhea treatment market research report is one of a series of new reports from The Business Research Company that provides difficile-associated diarrhea treatment market statistics, including difficile-associated diarrhea treatment industry global market size, regional shares, competitors with a difficile-associated diarrhea treatment market share, detailed difficile-associated diarrhea treatment market segments, market trends and opportunities and any further data you may need to thrive in the difficile-associated diarrhea treatment industry. This difficile-associated diarrhea treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The difficile-associated diarrhea treatment market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to prevalence of hospital-acquired infections, aging population, increasing prevalence of clostridium difficile infections, increasing urbanization.

The difficile-associated diarrhea treatment market size is expected to see rapid growth in the next few years. It will grow to $5.8 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to patient awareness, emerging therapies, global health initiatives, increasing demand for antimicrobial therapy, climate change, demand for self-administered treatments. Major trends in the forecast period include personalized treatment, telemedicine for follow-up, research into novel therapies, advancements in diagnostic techniques.

The increasing prevalence of digestive disorders is poised to act as a driving force behind the growth of the market for treating Clostridium difficile-associated diarrhea. Digestive disorders encompass a group of medical conditions that disrupt the normal functioning of the digestive system, responsible for the breakdown of food and the absorption of nutrients. Clostridium difficile (C. diff) infection is closely linked to digestive disorders, particularly diarrhea and colitis. This bacterium, Clostridium difficile, infects the bowel by producing toxins that induce inflammation and damage the intestinal lining. As more individuals are diagnosed with digestive disorders, there is a growing demand for effective treatments to manage symptoms associated with Clostridium difficile-associated diarrhea. For instance, as of June 2023, data from Crohn's and Colitis Canada, a non-profit organization based in Canada, indicated that an estimated 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting approximately 0.82% of the population. Additionally, projections suggest that around 470,000 Canadians will be living with IBD by 2035, representing about 1.1% of the population, or approximately 1 in every 91 individuals in the country. Consequently, the rising prevalence of digestive disorders is expected to drive the growth of the Clostridium difficile-associated diarrhea treatment market.

The growing prevalence of Clostridium difficile infection (CDI) is anticipated to be a key driver of the expansion of the market for treating Clostridium difficile-associated diarrhea. Clostridium difficile infection, or CDI, is attributed to the bacterium Clostridium difficile, which predominantly affects the colon, produces toxins that harm the colon lining, and leads to symptoms such as diarrhea, abdominal pain, and potentially life-threatening complications. CDI serves as the primary cause of Clostridium Difficile-Associated Diarrhea (DAD), and effectively managing CDI is imperative for addressing and resolving DAD. For instance, as of January 2023, data from the National Library of Medicine, a US-based medical library under the federal government, reported estimates from the Centers for Disease Control (CDC) indicating that approximately half a million Americans are afflicted by C. difficile infection annually. Among these cases, an estimated 29,000 patients experience fatal outcomes within one month of diagnosis, with 15,000 of these deaths directly linked to C. difficile infection. Additionally, about 83,000 patients encounter at least one recurrence of the disease, with 29,000 succumbing to the initial diagnosis within 30 days. Therefore, the escalating prevalence of Clostridium difficile infection is projected to drive the growth of the Clostridium difficile-associated diarrhea treatment market.

Prominent companies in the difficile-associated diarrhea treatment market are actively engaged in the development of innovative drugs and securing their approvals to maintain their market position. The approval of novel drugs for treating difficile-associated diarrhea is witnessing a significant upsurge due to the growing demand for more effective and safer treatment options. Notably, drugs like SER-109 are paving the way for innovative solutions in difficile-associated diarrhea treatment. For instance, in April 2023, the U.S. Food and Drug Administration (FDA), a federal agency based in the United States, granted approval for SER-109. SER-109 represents the first orally administered fecal microbiota product endorsed for preventing the recurrence of Clostridioides difficile diarrhea. This groundbreaking medication is developed by Seres Therapeutics, a biotechnology company headquartered in the United States. SER-109 is a live, spore-form probiotic that comes in capsule form. It comprises Firmicutes bacteria, which are naturally present in the human gut. The mechanism of SER-109 involves restoring the balance of bacteria in the stomach, thus aiding in the prevention of recurrent C. difficile infections. This innovative medication is designed to prevent the recurrence of Clostridioides difficile (C. diff) infection in individuals aged 18 and above who have undergone antibacterial treatment. The approval of such drugs is poised to transform the landscape of difficile-associated diarrhea treatment.

In April 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company headquartered in the United Kingdom, completed the acquisition of Custopharm Inc. for a sum of $375 million. This strategic acquisition is expected to bolster Hikma Pharmaceuticals PLC's research and development capabilities and pipeline, while also expanding its distinctive US portfolio to include nearly 130 commercially available injectable drugs. Custopharm Inc., based in the United States, specializes in generic sterile injectables production, with a focus on vancomycin, a medication used to treat Clostridium difficile-associated diarrhea (CDAD). This move solidifies Hikma Pharmaceuticals' presence and offerings in the US market.

Major companies operating in the difficile-associated diarrhea treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A.

North America was the largest region in the difficile-associated diarrhea treatment market in 2024. The regions covered in difficile-associated diarrhea treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the difficile-associated diarrhea treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The difficile-associated diarrhea treatment market consists of revenues earned by entities by providing conservative therapy, laboratory tests, colonoscopy and imaging tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The difficile-associated diarrhea treatment market also includes sales of oral rehydration solutions, electrolyte supplements and probiotics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Difficile-Associated Diarrhea Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on difficile-associated diarrhea treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for difficile-associated diarrhea treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The difficile-associated diarrhea treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Difficile-Associated Diarrhea Treatment Market Characteristics

3. Difficile-Associated Diarrhea Treatment Market Trends And Strategies

4. Difficile-Associated Diarrhea Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Difficile-Associated Diarrhea Treatment Growth Analysis And Strategic Analysis Framework

6. Difficile-Associated Diarrhea Treatment Market Segmentation

7. Difficile-Associated Diarrhea Treatment Market Regional And Country Analysis

8. Asia-Pacific Difficile-Associated Diarrhea Treatment Market

9. China Difficile-Associated Diarrhea Treatment Market

10. India Difficile-Associated Diarrhea Treatment Market

11. Japan Difficile-Associated Diarrhea Treatment Market

12. Australia Difficile-Associated Diarrhea Treatment Market

13. Indonesia Difficile-Associated Diarrhea Treatment Market

14. South Korea Difficile-Associated Diarrhea Treatment Market

15. Western Europe Difficile-Associated Diarrhea Treatment Market

16. UK Difficile-Associated Diarrhea Treatment Market

17. Germany Difficile-Associated Diarrhea Treatment Market

18. France Difficile-Associated Diarrhea Treatment Market

19. Italy Difficile-Associated Diarrhea Treatment Market

20. Spain Difficile-Associated Diarrhea Treatment Market

21. Eastern Europe Difficile-Associated Diarrhea Treatment Market

22. Russia Difficile-Associated Diarrhea Treatment Market

23. North America Difficile-Associated Diarrhea Treatment Market

24. USA Difficile-Associated Diarrhea Treatment Market

25. Canada Difficile-Associated Diarrhea Treatment Market

26. South America Difficile-Associated Diarrhea Treatment Market

27. Brazil Difficile-Associated Diarrhea Treatment Market

28. Middle East Difficile-Associated Diarrhea Treatment Market

29. Africa Difficile-Associated Diarrhea Treatment Market

30. Difficile-Associated Diarrhea Treatment Market Competitive Landscape And Company Profiles

31. Difficile-Associated Diarrhea Treatment Market Other Major And Innovative Companies

32. Global Difficile-Associated Diarrhea Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Difficile-Associated Diarrhea Treatment Market

34. Recent Developments In The Difficile-Associated Diarrhea Treatment Market

35. Difficile-Associated Diarrhea Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기